Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening
23 Fevereiro 2022 - 10:00AM
Business Wire
Methodology developed by QIMR Berghofer researchers utilizing
the Agilent Cary 630 FTIR Spectrometer
Agilent Technologies Inc. (NYSE: A) announced today that
researchers from the QIMR Berghofer Medical Research Institute in
Brisbane, Australia, collaborated with Agilent experts on a
proof-of-concept FTIR-based saliva COVID-19 testing workflow using
the Agilent Cary 630 FTIR Spectrometer.
The study investigated the pathophysiological response to a
COVID-19 infection through ATR-FTIR spectroscopy. The researchers
acquired infrared spectra of saliva samples following a quick and
simple sample preparation requiring only ethanol and basic
laboratory equipment. An infrared spectrum can be considered as a
biochemical snapshot of the saliva sample including a COVID-19
immune response signature.
Unlike other testing technologies such as PCR testing or rapid
antigen test, the ATR-FTIR method analyses the pathophysiological
responses of the human body rather than detecting the
pathogen/antigen itself, which is thought to make this method more
robust against virus mutations.
“We applied a simple ethanol decontamination procedure for
biosafe handling of self-collected saliva samples. A basic step of
significant importance for any test that has the potential to be
used in non-clinical environments such as in remote areas or in
scenarios where large crowds require rapid testing, for example, in
airports, or sports stadiums,” explained associate professor
Michelle Hill, head of QIMR Berghofer’s Precision and Systems
Biomedicine Research Group, and one of the lead scientists of the
study.
“Earlier research studies on ATR-FTIR for COVID-19 saliva
testing were not conclusive on the biological basis for the saliva
testing methodology. To shine a light on this aspect, we also
conducted controlled infection experiments on cells and mice models
and established the most characteristic COVID-19 positive spectral
signature. We integrated our data from in vitro cell studies, in
vivo mouse studies, and independent human cohort studies, as well
as data from recent publications to demonstrate the robustness of
the methodology,” Hill added.
The paper titled Pathophysiological
Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy
Enables Rapid and Robust Saliva Screening for COVID-19 has
been published in the journal Biomedicines. The results demonstrate
the advantage of using the Cary 630 FTIR Spectrometer in advanced
infectious disease research. Specifically, the instrument’s
ultra-compact, portable, and reliable design makes it ideal for
seamless deployment in different settings and scenarios in
infectious disease research.
“We are very excited about this research study. FTIR
spectroscopy is an easy-to-use analytical technique, uses minimal
consumables, and provides results in seconds,” said Andrew Hind,
associate vice president of Research and Development for the
Molecular Spectroscopy Division at Agilent. “It emphasizes the
potential of ATR-FTIR spectroscopy for life science and infectious
disease research. Agilent funded parts of this research work
through the Agilent Technologies Applications and Core Technology -
University Research Grant and provided the Cary 630 FTIR
Spectrometer. We will continue to support work in the field of
COVID-19 and infectious diseases research.”
The research was further funded by the QIMR Berghofer Medical
Research Institute and The Prince Charles Hospital Research
Foundation.
About Agilent Technologies Agilent Technologies Inc.
(NYSE: A) is a global leader in the life sciences, diagnostics, and
applied chemical markets, delivering insight and innovation to
advance the quality of life. Agilent’s full range of solutions
includes instruments, software, services, and expertise that
provide trusted answers to our customers' most challenging
questions. The company generated revenue of $6.32 billion in fiscal
2021 and employs 17,000 people worldwide. Information about Agilent
is available at www.agilent.com. To
receive the latest Agilent news, please subscribe to the Agilent
Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220223005764/en/
Media Contact Naomi Goumillout Agilent Technologies
+1.781.266.2819 naomi.goumillout@agilent.com
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024